Want to see HK:9995 full AI Analyst Report?
Top Page
RemeGen Co. Ltd. Class H
(9995)
Select Model
Select Model
Rating:66Neutral
Price Target:
HK$70.00
▼(-15.15% Downside)
Action:Downgraded
Date:10/31/26
The score is driven by strong recent financial performance (sharp profitability and cash-flow turnaround with low leverage) and a low P/E that suggests favorable valuation if earnings hold. Offsetting this, technical signals are weak, with the price below all key moving averages and negative MACD, indicating the market trend remains bearish despite improved fundamentals.
Positive Factors
Strong revenue and profitability inflection
The sharp TTM revenue increase and exceptionally high profitability demonstrate substantial current commercial traction for the company’s therapies. If these results persist, stronger earnings can support reinvestment in clinical development, commercialization, and the broader proprietary product pipeline over coming quarters.
Negative Factors
Earnings durability remains uncertain
The abrupt shift from losses and cash burn to exceptionally high profitability makes the current earnings base difficult to underwrite as a stable trend. Results may remain lumpy if they depend on product mix, milestones, or other factors that do not repeat consistently.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue and profitability inflection
The sharp TTM revenue increase and exceptionally high profitability demonstrate substantial current commercial traction for the company’s therapies. If these results persist, stronger earnings can support reinvestment in clinical development, commercialization, and the broader proprietary product pipeline over coming quarters.
Read all positive factors
RemeGen Co. Ltd. Class H (9995) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$51.82B
Dividend YieldN/A
Average Volume (3M)1.87M
Price to Earnings (P/E)7.9
Beta (1Y)0.93
Revenue Growth292.84%
EPS GrowthN/A
CountryHK
Employees3,145
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)11.64
Shares Outstanding208,581,240
10 Day Avg. Volume1,813,762
30 Day Avg. Volume1,865,016
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)9.84
Price to Sales (P/S)10.96
P/FCF Ratio-253.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$118.47Price Target Upside43.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)7.71
Revenue Forecast (FY)HK$7.60B
RemeGen Co. Ltd. Class H Business Overview & Revenue Model
Company Description
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telit...
How the Company Makes Money
RemeGen primarily makes money through the commercialization of its proprietary drug products, where revenue is generated from product sales (i.e., selling approved therapies into healthcare channels such as hospitals, pharmacies, and/or distributo...
RemeGen Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
72
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.24B | 3.24B | 1.72B | 1.08B | 767.77M | 1.42B |
| Gross Profit | 7.60B | 2.82B | 1.37B | 822.99M | 497.84M | 1.36B |
| EBITDA | 5.26B | 431.72M | -1.12B | -1.25B | -805.70M | 402.05M |
| Net Income | 6.49B | 709.65M | -1.47B | -1.51B | -997.84M | 276.26M |
Balance Sheet | ||||||
| Total Assets | 10.54B | 7.25B | 5.50B | 5.53B | 6.02B | 4.16B |
| Cash, Cash Equivalents and Short-Term Investments | 5.51B | 2.42B | 759.53M | 709.07M | 2.07B | 1.76B |
| Total Debt | 292.23M | 2.20B | 2.67B | 1.26B | 165.03M | 102.78M |
| Total Liabilities | 1.65B | 3.64B | 3.51B | 2.09B | 1.04B | 712.79M |
| Stockholders Equity | 8.89B | 3.61B | 1.99B | 3.44B | 4.98B | 3.45B |
Cash Flow | ||||||
| Free Cash Flow | 3.83B | -140.08M | -1.38B | -2.35B | -2.02B | -353.71M |
| Operating Cash Flow | 3.96B | 54.75M | -1.11B | -1.50B | -1.26B | 263.63M |
| Investing Cash Flow | -2.44B | -203.49M | -248.24M | -817.65M | -841.56M | -637.95M |
| Financing Cash Flow | -1.63B | 537.67M | 1.39B | 978.31M | 2.43B | -626.90M |
RemeGen Co. Ltd. Class H Technical Analysis
Negative
82.50
Price Trends
73.41
Negative
76.24
Negative
83.69
Negative
Market Momentum
-2.98
Negative
41.89
Neutral
55.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9995, the sentiment is Negative. The current price of 82.5 is above the 20-day moving average (MA) of 67.32, above the 50-day MA of 73.41, and below the 200-day MA of 83.69, indicating a bearish trend. The MACD of -2.98 indicates Negative momentum. The RSI at 41.89 is Neutral, neither overbought nor oversold. The STOCH value of 55.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9995.
RemeGen Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$51.82B | 7.90 | 105.60% | ― | 292.84% | ― | |
65 Neutral | HK$16.81B | 12.42 | 17.47% | ― | 146.27% | ― | |
60 Neutral | HK$26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$76.70B | -66.50 | -10.86% | ― | 42.47% | -15.80% | |
47 Neutral | HK$6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% | |
41 Neutral | HK$30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
HK:9995
RemeGen Co. Ltd. Class H
64.85
-25.15
-27.94%
HK:9926
Akeso, Inc.
81.50
-31.90
-28.13%
HK:9966
Alphamab Oncology
6.22
-5.29
-45.96%
HK:9969
InnoCare Pharma Ltd.
11.25
-3.00
-21.05%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
15.26
-11.32
-42.59%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
49.06
-20.79
-29.76%
RemeGen Co. Ltd. Class H Corporate Events
RemeGen Issues Unaudited 2026 Third-Quarter Report and Cautions Investors
Oct 29, 2026
RemeGen Co., Ltd. has released an unaudited third-quarter report for 2026 prepared under PRC accounting principles to meet STAR Market disclosure requirements, while reminding investors that these figures differ from International Financial Report...
RemeGen Sets Board Meeting to Approve Third-Quarter Results
Oct 16, 2026
RemeGen Co., Ltd., a Hong Kong-listed biopharmaceutical company incorporated in the People’s Republic of China, develops and commercializes innovative therapeutic products, serving investors who track its financial and RD progress in the glo...
RemeGen Deploys Idle Funds Into RMB670 Million SPDB Wealth Products
Oct 14, 2026
RemeGen Co., Ltd. has expanded its use of idle self-owned funds for cash management by purchasing additional wealth management products from SPDB Yantai Branch. On October 14, 2026, the company entered into two new agreements totaling RMB370 milli...
RemeGen Reshapes Company Secretariat and Hong Kong Representation Roles
Sep 28, 2026
RemeGen Co., Ltd. announced a change in its corporate governance structure, confirming that the Hong Kong Stock Exchange has recognized Mr. Tong Shaojing as having the requisite experience to serve as company secretary under applicable listing rul...
RemeGen Deploys Idle Funds Into Discloseable Wealth Management Products
Sep 2, 2026
RemeGen Co., Ltd., a PRC-based biopharmaceutical company listed in Hong Kong under stock code 9995, focuses on innovative biologic drug development and commercialization. Its capital-intensive operations are supported by self-owned funds and A-sha...
RemeGen Delivers Surging Interim Revenue as Key Biologic Therapies Secure New Approvals and Milestones
Aug 24, 2026
RemeGen Co., Ltd. reported a sharp rise in interim revenue to RMB5,850.2 million for the six months ended June 30, 2026, a 435.74% increase year-on-year driven by robust sales of its commercial-stage drugs telitacicept and disitamab vedotin, as we...
RemeGen Sets Out Board Structure and Key Governance Committees
Aug 24, 2026
RemeGen Co., Ltd. has announced the current composition of its board of directors, comprising five executive directors, one non-executive director and three independent non-executive directors. The chairman of the board, together with the employee...
RemeGen Commits US$100 Million of Idle Funds to OCBC Wealth Products in Discloseable Transaction
Aug 18, 2026
RemeGen Co., Ltd., a PRC-based biopharmaceutical company listed in Hong Kong, develops and commercializes innovative biologic therapies for autoimmune and oncology indications across domestic and global markets. The company leverages its listing t...
RemeGen Sets Board Meeting to Approve Interim 2026 Results
Aug 12, 2026
RemeGen Co., Ltd. has scheduled a board meeting for August 24, 2026 to review and approve the interim results for the six months ended June 30, 2026. The company also plans to publish these interim results following board approval, a step that wil...
RemeGen Forecasts Major Profit Turnaround on Surging Drug Sales and AbbVie Licensing Deal
Aug 5, 2026
RemeGen Co., Ltd. has issued an inside information announcement estimating a sharp improvement in its financial performance for the six months ended June 30, 2026, under China Accounting Standards. The company expects operating revenue of about RM...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.